BHM® Anti-Viral Nasal Spray wins Med-Tech Innovation ‘Materials Innovation Award’
Birmingham Biotech is delighted to announce that the BHM® Anti-Viral Nasal Spray has won the ‘Materials Innovation Award’ at the Med-Tech Innovation Awards. BHM® Anti-Viral Nasal Spray is an easy-to-use nasal device designed to protect, capture and prevent the inhalation of infectious viruses, including SARS-CoV-2.
Michael Hsu, Managing Director at Birmingham Biotech commented, “We are thrilled that the BHM® Anti-Viral Nasal Spray has received this award. This recognition motivates us to continue working hard to develop innovative health technologies to tackle global health challenges and respond to future emergencies. We are now focusing on bringing the BHM® Anti-Viral Nasal Spray to patients around the world. The product launched in Singapore on 1st May 2022 and is also available in Hong Kong and Thailand. It will launch in the UK, Europe and Latin America later in the year, so watch this space…!”
In addition, Birmingham Biotech’s COVID-19 Sealing Tube Test was highly commended for the Med-Tech Innovation ‘Sustainability Award’. This lateral flow test uses 75% less plastic compared to traditional test kits, and is a symbol of Birmingham Biotech’s dedication to developing healthcare solutions that benefit both people and the planet.
The award ceremony took place on 8th June in Birmingham. Several of the Birmingham Biotech team attended the event, joined by Professor Liam Grover and Dr Richard Moakes - two members of the research team at the University of Birmingham that developed the formula for the BHM® Anti-Viral Nasal Spray.
The awards ceremony was a wonderful opportunity to celebrate the incredible talent and latest innovations in the UK med tech sector. Congratulations to all the winners and finalists!